Nacuity Pharmaceuticals

company

About

Nacuity Pharmaceuticals is a pharmaceutical company that aims to develop a breakthrough treatment for retinitis pigmentosa.

  • 11 - 50

Details

Last Funding Type
Series B
Last Funding Money Raised
$16.50M
Industries
Health Care,Pharmaceutical
Founded date
Jan 1, 2016
Number Of Employee
11 - 50
Operating Status
Active

Nacuity Pharmaceuticals is a pharmaceutical company that aims to develop a breakthrough treatment for retinitis pigmentosa (“RP”) and potentially other ophthalmological indications.

Nacuity has assembled an accomplished team and has received significant financial and technical support from the Foundation Fighting Blindness (FFB). FFB aims to drive research providing prevention, treatments and cures for people affected by blinding retinal diseases.

FFB has invested nearly $700 million in this effort Over the last 46 years. FFB is a significant supporter of Dr. Campochiaro’s research and has committed to fund a substantial portion of Nacuity’s Phase 1 and Phase 2 trials through a milestone-based matching program grant to Nacuity in support of our NPI-001 development program.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$16.50M
Nacuity Pharmaceuticals has raised a total of $16.50M in funding over 2 rounds. Their latest funding was raised on Jun 15, 2022 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 15, 2022 Series B $16.50M 2 Foundation Fighting Blindness Detail

Investors

Number of Lead Investors
Number of Investors
1
2
Nacuity Pharmaceuticals is funded by 2 investors. Foundation Fighting Blindness and Retinal Degeneration Fund are the most recent investors.
Investor Name Lead Investor Funding Round
Foundation Fighting Blindness Yes Series B
Retinal Degeneration Fund Series B